Quick Takeaways
- Baselake Partners, LP filed SCHEDULE 13G for TherapeuticsMD, Inc. Common Stock, par value $0.001 per share (TXMD).
- Disclosed ownership: 5.2%.
- Date of event: 30 Mar 2026.
Baselake Partners, LP - 30 Mar 2026 SCHEDULE 13G Report for TherapeuticsMD, Inc. Common Stock, par value $0.001 per share (TXMD)
- Filing Manager
- Baselake Partners, LP
- Reporting Manager
- Baselake Partners, LP
- Symbol
- TXMD
- Shares outstanding
- 11,676,558 shares
- Disclosed Ownership
- 607,181 shares
- Ownership
- 5.2%
- Form type
- SCHEDULE 13G
- Filing time
- 06 Apr 2026, 21:31:34 UTC
- Date of event
- 30 Mar 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"Baselake Partners, LP disclosed 5.2% ownership in TherapeuticsMD, Inc. Common Stock, par value $0.001 per share (TXMD) on 30 Mar 2026."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 06 Apr 2026, 21:31.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Baselake Partners, LP | 5.2% | 607,181 | 0 | 607,181 | /s/ David Paolella | David Paolella, Managing Member of Baselake Management, LLC, its investment manager | |
| Baselake Management, LLC | 5.2% | 607,181 | 0 | 607,181 | /s/ David Paolella | David Paolella, Managing Member | |
| David Paolella | 5.2% | 607,181 | 0 | 607,181 | /s/ David Paolella | Individually |